EP1063891A4 - Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby - Google Patents

Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby

Info

Publication number
EP1063891A4
EP1063891A4 EP99912710A EP99912710A EP1063891A4 EP 1063891 A4 EP1063891 A4 EP 1063891A4 EP 99912710 A EP99912710 A EP 99912710A EP 99912710 A EP99912710 A EP 99912710A EP 1063891 A4 EP1063891 A4 EP 1063891A4
Authority
EP
European Patent Office
Prior art keywords
antigen
methods
presenting cells
compositions produced
enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912710A
Other languages
German (de)
French (fr)
Other versions
EP1063891A2 (en
Inventor
Charles A Nicolette
Johanne Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1063891A2 publication Critical patent/EP1063891A2/en
Publication of EP1063891A4 publication Critical patent/EP1063891A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99912710A 1998-03-20 1999-03-19 Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby Withdrawn EP1063891A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7888098P 1998-03-20 1998-03-20
US78880P 1998-03-20
PCT/US1999/006031 WO1999047102A2 (en) 1998-03-20 1999-03-19 Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby

Publications (2)

Publication Number Publication Date
EP1063891A2 EP1063891A2 (en) 2001-01-03
EP1063891A4 true EP1063891A4 (en) 2002-10-23

Family

ID=22146768

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912710A Withdrawn EP1063891A4 (en) 1998-03-20 1999-03-19 Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby

Country Status (5)

Country Link
EP (1) EP1063891A4 (en)
JP (1) JP2002506622A (en)
AU (1) AU755156B2 (en)
CA (1) CA2322750A1 (en)
WO (1) WO1999047102A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
PT1794327T (en) * 2004-09-14 2017-01-24 Argos Therapeutics Inc Strain independent amplification of pathogens and vaccines thereto
WO2009008713A1 (en) * 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Tap-inhibitors from old world primate 1-herpesviruses and their use
CN104761644A (en) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 Fusion protein MBP-MART-1 expressed by Escherichia coli, and preparation method and application thereof
WO2016073748A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Biomarkers and targets for cancer immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015384A1 (en) * 1993-11-30 1995-06-08 Johnson David C Vector, viral protein, nucleotide sequence coding therefor and method for inhibiting immune recognition
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
WO1995015384A1 (en) * 1993-11-30 1995-06-08 Johnson David C Vector, viral protein, nucleotide sequence coding therefor and method for inhibiting immune recognition
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BANKS THERESA A ET AL: "Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.", VIROLOGY, vol. 200, no. 1, 1994, pages 236 - 245, XP002210423, ISSN: 0042-6822 *
JUGOVIC PIETER ET AL: "Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47.", JOURNAL OF VIROLOGY, vol. 72, no. 6, June 1998 (1998-06-01), pages 5076 - 5084, XP002210422, ISSN: 0022-538X *
LIU T ET AL: "TAP peptide transporter-independent presentation of heat-killed Sendai virus antigen on MHC class I molecules by splenic antigen-presenting cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 DEC 1997, vol. 159, no. 11, 1 December 1997 (1997-12-01), pages 5364 - 5371, XP002210421, ISSN: 0022-1767 *
NEUMANN LARS ET AL: "The active domain of the herpes simplex virus protein ICP47: A potent inhibitor of the transporter associated with antigen processing (TAP).", JOURNAL OF MOLECULAR BIOLOGY, vol. 272, no. 4, 1997, pages 484 - 492, XP002210420, ISSN: 0022-2836 *
WONG C ET AL: "INDUCTION OF PRIMARY, HUMAN ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VITRO USING DENDRITIC CELLS PULSED WITH PEPTIDES", JOURNAL OF IMMUNOTHERAPY, RAVEN PRESS, NEW YORK, NY, US, vol. 21, no. 1, 15 January 1998 (1998-01-15), pages 32 - 40, XP002919848, ISSN: 1053-8550 *

Also Published As

Publication number Publication date
JP2002506622A (en) 2002-03-05
AU755156B2 (en) 2002-12-05
CA2322750A1 (en) 1999-09-23
WO1999047102A2 (en) 1999-09-23
WO1999047102A3 (en) 1999-10-21
EP1063891A2 (en) 2001-01-03
AU3102399A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
GB2348808B (en) Methods and compositions for desensitisation
AU2001280189A1 (en) Air refining device and ion generator used for the device
AU3641597A (en) Methods and compositions comprising r-ibuprofen
GB2319180B (en) Mycobacterial compositions
AU7158398A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
AU6505299A (en) Methods for generating antigen-reactive t cells (in vitro)
AU7116798A (en) Silicon greases and methods for their production
AU2410999A (en) Presentation device
AUPO709197A0 (en) Improvements in electrotactile vocoders
AU4642600A (en) Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells
AU2664797A (en) Wnt receptor compositions and methods
EP1165773A4 (en) Advanced antigen presentation platform
EP1073333A4 (en) S-rabeprazole compositions and methods
EP1075184A4 (en) Compositions and methods for active vaccination
AU7134598A (en) Plant propagation compositions and methods
AU1750797A (en) Compositions and methods for mediating cell cycle progression
EP1063891A4 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
AU7308200A (en) Novel hev antigenic peptide and methods
GB9705744D0 (en) Methods for selecting cells and their uses
AU7358098A (en) Radioisotope concentrator methods and compositions
AUPO982097A0 (en) Methods and compositions for use therein
AU2001261534A1 (en) The meca-79 antigen and related methods
AU7442296A (en) Generating d-peptides: methods and compositions
AU8513698A (en) Methods and compositions for designing vaccines
EP1071325A4 (en) Compositions and methods for antigen-specific vaccination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000920

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020911

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20021219